Santhera Pharmaceuticals Holding AG / Fundamentals
Income statement
- Net revenue
€154.23M - Cost of goods sold
€21.37M - Gross profit
€132.86M - SG&A expenses
€65.47M - R&D expenses
€48.86M - EBITDA
€67.98M - D&A
€9.40M - EBIT
€18.59M - Interest expenses
€53.59M - EBT
€14.24M - Tax expenses
€379.91K - Net income
€13.86M
Cash flow statement
- Net deferred tax
-€4.98M - Non-cash items
€4.40M - Changes in working capital
-€21.24M - Operating cash flow
€12.71M - Capex
€260.85K - Other investing cash flow
-€22.42M - Net investing cash flow
-€19.60M - Total cash dividends paid
€0.00 - Issuance of common stock
€31.64M - Debt repayment
€8.33M - Other financing cash flow
€9.72M - Net financing cash flow
€49.69M - Foreign exchange effects
€1.84M - Net change in cash
€16.38M - Cash at end of period
€44.30M - Free cash flow
€12.97M
Balance sheet
- Cash and cash equivalents
€44.30M - Cash and short-term investments
€44.30M - Total receivables
€15.03M - Inventory
€18.97M - Other current assets
€3.76M - Total current assets
€82.06M - Property, plant & equipment
€2.78M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€265.18K - Other non-current assets
€0.00 - Total non-current assets
€82.99M - Total assets
€165.05M - Accounts payable
€9.98M - Short-term debt
€7.52M - Other current liabilities
€32.38M - Total current liabilities
€49.94M - Long-term debt
€36.44M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€46.60M - Total non-current liabilities
€85.13M - Total liabilities
€135.07M - Common stock
€1.45M - Retained earnings
-€665.32M - Other equity
-€3.57M - Total equity
€29.98M - Total liabilities and shareholders' equity
€165.05M
Company information
- Market capitalization
€165.11M - Employees
78 - Enterprise Value
€165.09M
Company ratios
- Gross margin
-
86.1% Much better than peer group: -134.4% - EBITDA margin
-
44.1% Much better than peer group: -1,100.7% - EBIT margin
-
12.1% Much better than peer group: -1,187.1% - EBT margin
-
9.2% Much better than peer group: -1,192.4% - Net margin
-
9.0% Much better than peer group: -1,190.2% - ROE
-
46.2% Much better than peer group: -72.7% - ROA
-
8.4% Much better than peer group: -63.5% - Asset turnover
-
93.4% Much better than peer group: 30.8% - FCF margin
-
8.1% Much better than peer group: -1,013.2% - FCF yield
7.5% - Efficiency ratio
55.9% - Net sales per employee
-
€1.98M - Net income per employee
-
€177.73K